Sensei Biotherapeutics, Inc. (NASDAQ: SNSE)

Sensei Biotherapeutics, Inc. (SNSE), a company operating in the immuno-oncology industry, is dedicated to the discovery and development of next-generation therapeutics for cancer patients. The company's main business activities revolve around the creation of highly selective therapeutics that either disable immunosuppressive signals or activate immunostimulatory signals specifically in the tumor microenvironment.

The company's revenue generation is primarily through the development and commercialization of its product candidates, with SNS-101 being a significant one. SNS-101 is a conditionally active monoclonal antibody targeting VISTA, an important immunoregulatory target highly expressed on various immune system cells, including myeloid lineage cells such as neutrophils, monocytes, macrophages, basophils, and dendritic cells.

Sensei Biotherapeutics has a competitive advantage in the development of VISTA-targeting antibodies due to its proprietary TMAb platform. This platform is designed to generate highly selective therapeutics by utilizing yeast-based surface display technology of antibody libraries to identify rare clones that exhibit desired binding properties under tumor-like biochemical parameters. SNS-101 is a prime example of this, as it was designed to overcome the challenges of previous anti-VISTA monoclonal antibodies by selectively binding to VISTA at low pH, avoiding binding to VISTA in the blood, and utilizing an Fc-competent IgG backbone to engage and activate FcgR+ myeloid cells within the tumor.

Preclinical studies have shown the potential of SNS-101 to enhance anti-PD-1 response and promote a shift towards a pro-inflammatory and anti-tumor state. The antibody has been shown to accumulate in the tumor microenvironment, where it can bind to VISTA+ cells and inhibit their immunosuppressive activity. A Phase 1/2 open-label, multi-center, dose escalation and expansion trial has been initiated to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 as monotherapy and/or in combination with cemiplimab in patients with advanced solid tumors.

In the immuno-oncology space, Sensei Biotherapeutics is a relatively new company but has made significant progress in the development of its product candidates. The company's TMAb platform and proprietary technology have the potential to differentiate it from other companies in the industry. However, its success will depend on its ability to obtain regulatory approval for its product candidates and to commercialize them successfully.

The company's customers are not disclosed in the text provided, as no specific customers have been announced. However, the company's product candidates, including SNS-101, are being developed for the treatment of various types of cancer, including solid tumors.

In addition to SNS-101, Sensei Biotherapeutics has other primary products, including SNS-102, SNS-103, and SNS-201. These are conditionally active monoclonal antibodies targeting VSIG4, ENTPDase1, and CD28, respectively.